← feed

Is NCT02480374 results overdue?

Yes — results are overdue. Primary completion was 2017-05; the FDAAA-801 reporting deadline (2018-05-31) passed 2943 days ago and no results are posted on ClinicalTrials.gov.

Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer

NCT IDNCT02480374 ↗
SponsorImunon (INDUSTRY)
Public issuerImunon, Inc. — IMNN (CIK 0000749647) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-05 (ACTUAL)
Reporting deadline2018-05-31 (completion + 365d)
Days overdue2943
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 31d186e3a152c64f… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02480374. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →